Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNotes PayablesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal Liabilities
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Universe Pharmaceuticals (UPC) Receivables (2020 - 2025)

Universe Pharmaceuticals' Receivables history spans 6 years, with the latest figure at $2.3 billion for Q3 2025.

  • For Q3 2025, Receivables fell 86.22% year-over-year to $2.3 billion; the TTM value through Sep 2025 reached $2.3 billion, down 86.22%, while the annual FY2025 figure was $2.3 billion, 36.03% down from the prior year.
  • Receivables for Q3 2025 was $2.3 billion at Universe Pharmaceuticals, down from $16.6 billion in the prior quarter.
  • Across five years, Receivables topped out at $16.6 billion in Q3 2024 and bottomed at $12.9 million in Q3 2023.
  • The 5-year median for Receivables is $16.3 million (2021), against an average of $3.8 billion.
  • The largest annual shift saw Receivables skyrocketed 128258.49% in 2024 before it tumbled 86.22% in 2025.
  • A 5-year view of Receivables shows it stood at $16.3 million in 2021, then dropped by 6.6% to $15.2 million in 2022, then decreased by 14.81% to $12.9 million in 2023, then surged by 128258.49% to $16.6 billion in 2024, then crashed by 86.22% to $2.3 billion in 2025.
  • Per Business Quant, the three most recent readings for UPC's Receivables are $2.3 billion (Q3 2025), $16.6 billion (Q3 2024), and $12.9 million (Q3 2023).